Ascendis Pharma A/S
ASND
Updated: 24/09/2026, 09:28:51
Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing therapeutic solutions for critical medical conditions that currently lack effective treatments. Its commercialized offering is SKYTROFA, a therapy prescribed for individuals suffering from growth hormone deficiency (GHD). The company boasts a robust development pipeline, featuring several TransCon-branded candidates. These include TransCon Growth Hormone (hGH), which is being progressed for pediatric GHD patients in Japan and for adults with GHD. Also under development are TransCon parathyroid hormone for adults with hypoparathyroidism, and TransCon CNP, aimed at treating pediatric achondroplasia. Further expanding its innovative portfolio, Ascendis is also developing a TransCon toll-like receptor (TLR) 7/8 agonist for intratumoral administration, alongside TransCon IL-2 ß/g, designed for systemic delivery. Founded in 2006, this enterprise maintains its corporate headquarters in Hellerup, Denmark.
No summaries found.
- Share price
- $223.13
- Market cap
- $13.86B
- Exchange
- NASDAQ
- Currency
- USD
- CEO
- Jan Moller Mikkelsen
- Employees
- 1,189
- IPO date
- 28/01/2015
- Beta
- 0.382
- Last dividend
- $0.00
- Day range
- $220.60 – $237.98
- 52-week range
- $186.05 – $282.15
- 1-day performance
- -6.08%
- 1-year performance
- 19.93%
- Current drawdown (1Y)
- -20.92%
- CIK
- 0001612042
- CUSIP
- K08588103
- ISIN
- DK0060615755
- Created
- 07/12/2025, 02:10:50
- Last update
- 24/09/2026, 09:28:51
Track Ascendis Pharma A/S with an AI analyst
See which prediction-market events move ASND, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
Ascendis Pharma: Rare Endocrine Compounder Entering Growth Phase (Initiating Buy)
Seeking Alpha • STOCK • 28/05/2026, 02:16:34
Ascendis Pharma A/S (ASND) Q1 2026 Earnings Call Transcript
Seeking Alpha • STOCK • 09/05/2026, 03:01:16
Ascendis to Report First Quarter 2026 Financial Results and Provide Business Update on May 7, 2026
GlobeNewsWire • STOCK • 30/04/2026, 18:01:00
Ascendis Announces Redemption of All $575 Million of Outstanding 2.25% Convertible Senior Notes Due 2028
GlobeNewsWire • STOCK • 21/04/2026, 18:31:00
Ascendis Receives Orphan Drug Exclusivity and Launches YUVIWEL® (Navepegritide) in the United States
GlobeNewsWire • STOCK • 06/04/2026, 18:01:00
New InsiGHTS Trial of TransCon® hGH (Lonapegsomatropin) in Turner Syndrome Demonstrated Comparable Efficacy and Safety to Daily Somatropin at Week 52
GlobeNewsWire • STOCK • 17/03/2026, 09:30:00
Ascendis Pharma A/S (NASDAQ:ASND) Price Target and Market Performance
Market Data • Market Data • 06/03/2026, 01:02:39
Ascendis Pharma A/S (ASND) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Seeking Alpha • STOCK • 04/03/2026, 15:42:13
Ascendis Pharma: Yuviwel Approved Despite Legal Challenges
Seeking Alpha • STOCK • 03/03/2026, 13:05:28
Ascendis Pharma A/S (NASDAQ:ASND) Gains Momentum with FDA Approval and Upgraded Rating
Market Data • Market Data • 02/03/2026, 18:11:49
Ascendis Pharma A/S (ASND) Discusses FDA Approval and Commercial Launch Plans for YUVIWEL Transcript
Seeking Alpha • STOCK • 02/03/2026, 17:57:59
Ascendis wins U.S. approval for therapy for children with dwarfism
Reuters • STOCK • 27/02/2026, 19:04:25